‘Get Sicker’: Anatomy Of A Failed Policy

‘Get Sicker’: Anatomy Of A Failed Policy

By Mary Beth Pfeiffer

Twenty-seven-year-old Ankit Dubey was sick and terrified. He could hear sirens blaring across Lucknow, his home in northern India. He had been warned away from hospitals. People in his middle-class neighborhood were dying.

This second COVID wave was nothing like the first in 2020. This was Armageddon, “a horror movie,” he said, that lasted through April and May of 2021. He had thought lockdowns had spared India the chaos he had seen on TV from New York and Rome. He was wrong. “We went through hell,” he said.

Dubey told me his story because he wants the West to understand, to know. He, his parents, 56 and 65, and brother, 30, all four sick, were spared death, thankfully, but also painful and prolonged illness. How? They got treated early with a combination of safe generic drugs: azithromycin, doxycycline, and another he had never heard of: ivermectin. Other Indians tell similar stories.

India has been cast as a COVID failure with a struggling health-care system and spotty access to vaccines. But despite those two realities, India quelled a vicious Delta wave by making a key choice. Most of its states, led by ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee